EUCTR2012-001947-31-DE进行中（未招募）不适用
Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial - CLL-X4
Technische Universität Dresen0 个研究点开始时间: 2012年7月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Diagnosis of CLL according to WHO criteria confirmed by flow cytometry of peripheral blood or bone marrow
- •- Age > 55 years
- •- Poor-risk disease according to the EBMT CLL Transplant Consensus:
- •=>Non-response or early relapse (within 12 months) after purine analogue-containing therapy
- •=>Relapse (within 24 months) after purine analogue combination therapy or treatment of similar efficacy (ie, autologous stem cell transplantation)
- •=>p53 deletion/mutation (del 17p-) requiring treatment
- •- Measurable disease in the peripheral blood defined by a minimum clonal lymphocyte count of 0.5 GPT/L at the time of study inclusion
- •- Medically fit patients eligible for allogeneic HCT
- •- Informed consent for related and unrelated donor search and the goal to perform allogeneic HCT
- •-Sexually mature males must agree to use adequate and medically accepted method of contraception throughout the study if their sexual partners are woman of child bearing potential (WOCBP)
- •-WOCBP must be using an adequate and medically accepted method of contraception to avoid pregnancy throughout the study and for at least 3 months after the study. WOCBP includes any female that has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >12 consecutive months); or woman on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35mlU/mL.
- •-WOCBP must have a negative serum or urin pregnancy test prior to the start of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 71
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 71
排除标准
- •- Richter’s transformation in current relapse or active disease
- •- Prior allogeneic HCT
- •- Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to enrollment, whichever is longer, or participation in any other interventional clinical study
- •- Non-response to monotherapy with ofatumumab prior to study inclusion
- •- Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months prior to randomization, congestive heart failure (left ventricular ejection fraction < 50%).
- •- Abnormal renal function defined by an estimated GFR < 50ml/min
- •- Abnormal lung function tests defined by a DLCO <50%, FEV1%VC <70% despite appropriate treatment
- •- Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg or HBcAb.
- •- Positive serology for hepatitis C (HC) defined as a positive test for anti-HCV, confirmed by PCR.
- •- Screening laboratory values:
- •=>total bilirubin >1.5 times upper normal limit (unless due to AIHA or a known history of Gilbert’s disease)
- •=>ALT or AST >2.5 times upper normal limit
- •=>Gamma glutamyl transpeptidase (GGT) >2.5 times upper normal limit (unless due to disease involvement of the liver)
- •- Other past or current hematologic or solid organ malignancy. Subjects who have been free of malignancy for at least 3 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.
- •- Male subjects unable or unwilling to use adequate contraception methods from study start to one year after the last dose of protocol therapy.
- •- Pregnant or lactating woman
- •- Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease which in the opinion of the investigator may represent a risk for the patient
研究者
相似试验
已完成
2 期
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic TransplantationChronic Lymphatic LeukemiaNCT01809847Technische Universität Dresden20
已完成
2 期
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT01444716M.D. Anderson Cancer Center34
已完成
4 期
Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaRelapsing Multiple SclerosisNCT05199571Novartis Pharmaceuticals99
进行中（未招募）
1 期
A clinical trial to investigate efficacy and safety of continous treatment with bevacizumab together with chemotherapy in elderly patients with metastasized colorectal cancerMetastatic colorectal cancerEUCTR2014-003844-11-SEDepartment of Oncology, Linköping University Hospital, Linköping, Sweden48
已完成
2 期
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT01113632SCRI Development Innovations, LLC77